BEATW · HeartBeam, Inc.

HeartBeam, Inc. executed a material definitive underwriting agreement on April 14, 2026 with Titan Partners Group LLC, completing the offering on April 16, 2026. The transaction involved issuing 12,500,000 shares of common stock at a public offering price of $0.80 per share, with the underwriter purchasing at $0.744 per share, yielding gross proceeds of $10 million before discounts and expenses. This represents significant dilution but provides critical non-dilutive growth capital at this stage. Key terms include a 30-day over-allotment option for 1,875,000 additional shares and issuance of underwriter warrants covering 625,000 shares (5% of offering) exercisable immediately at $0.92 through April 14, 2031. A 75-day lock-up restricts Company and insider sales, signaling alignment with shareholders. Proceeds target commercialization of the FDA-cleared 12-lead synthesized ECG system, development of extended-wear patch and heart attack detection, AI enhancements, and general working capital—directly supporting pipeline advancement in a capital-intensive medtech sector. The offering's participation by the first commercial customer (ClearCardio), executives, board, and existing investors validates technology traction and strategic direction, potentially de-risking execution while bolstering the balance sheet for near-term milestones.